Published in Gene Therapy Weekly, June 16th, 2005
"Adoptive immunotherapy with tumor-specific T cells is an emerging technology that may be applicable to a broad range of cancers. However, tumors can avoid T cell-mediated attack through multiple mechanisms, including downregulation of major histocompatability complex (MHC)," scientists in England report.
"Consequently, engineering T cells to target intact protein antigen directly, thus bypassing the need for MHC presentation, can facilitate T cell targeting of tumor cells," E.J. Cheadle and colleagues, Paterson Institute for Cancer Research, Cancer Research U.K., Department of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.